Condition: Pancreatic Cancer · Circulating Tumor Cell · Predictive Cancer Model · Sponsor: Elisabethinen Hospital
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.
This description comes directly from the study's public registry record.
Patrick Kirchweger, MD, PhD · +436644159646 · patrick.kirchweger@ordensklinikum.at
Helwig Wundsam, PD, MD · +4373276774562 · helwig.wundsam@ordensklinikum.at
Always discuss trial participation with your own doctor first.
| Ordensklinikum Linz Barmherzige Schwestern | Linz, Upper Austria, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06391892